Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-DN-01 in Painful Diabetic Peripheral Neuropathy
NCT01793350Phase 2Withdrawn
- Sponsor
- BioChemics, Inc.
- Start
- Jun 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BC-DN-01 in diabetic peripheral neuropathy (DPN) (3 arms), sponsored by BioChemics, Inc. Primary endpoint: Reduction in DPN pain measured by the Brief Pain Inventory at 12 weeks. Planned start Jun 2013; status: withdrawn.
02
Drugs
BC-DN-01
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT01793350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01793350.